Home
ImmunityBio

ImmunityBio Market Share Analysis for April 2026

Contact us if you or a loved one has been diagnosed with cancer. Explore our clinical trials and find sites across the US to join our mission toward a cure.

Health > Biotechnology and Pharmaceuticals

Domainimmunitybio.com

Year Founded2014

Employees501 - 1000

Annual Revenue$25M - $50M

ImmunityBio

ImmunityBio (including company regionals)

immunitybio.com

See more website traffic and engagement information

ImmunityBio Revenue up to April 2026 is 25M - 50M

revenue generated by ImmunityBio top domains

ImmunityBio top domains revenue over 3 years

Revenue for ImmunityBio top domains

immunitybio.com25M - 50M

See more with Sales Intelligence

Total visits to ImmunityBio's top domains

Understand ImmunityBio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

immunitybio.com85K

See more with Sales Intelligence

Avg. visit duration in ImmunityBio's top domains

Analyze ImmunityBio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

immunitybio.com00:00:43

See more with Sales Intelligence

Avg. pageviews on ImmunityBio's top domains

See how ImmunityBio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

immunitybio.com1.73

See more with Sales Intelligence

ImmunityBio top competitors by domain

Top similar sites in April 2026, ranked by their affinity

alexion.comCompany NameAlexionEmployees1001 - 5000HQUnited States, Massachusetts, BostonAnnual revenue> $1BTotal visits62.2KHealth > Biotechnology and Pharmaceuticals

Top technologies used by ImmunityBio

These are the website technologies, by industry, used by ImmunityBio top domains

Advertising (12)

DoubleClick

Payment & Currencies (9)

Cart Functionality

Widget (7)

Twemoji

Conversion & Analytics (5)

Google Analytics

More Technologies

13

See all

News & Signals from ImmunityBio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsImmunityBio, Inc. attended event 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting on Jan 1st '26.ImmunityBio announced preliminary findings from a new health economic analysis presented at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, showing that ANKTIVA(R)(nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrated lower costs per sustained complete responder and per cystectomy avoided compared with TAR-200 in patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ (NMIBC CIS).

NewsImmunityBio, Inc. had issues with securities Law violations on May 22nd '26.NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) - Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ: IBRX) ("ImmunityBio" or the "Company") for potential violations of the federal securities laws.

NewsImmunityBio, Inc. attended event AUA 2026 on Jan 1st '26.ImmunityBio presented new comparative data at AUA 2026 showing ANKTIVA(R)(nogapendekin alfa inbakicept-pmln) plus BCG delivers longer-lasting responses and fewer adverse events than FDA-approved therapies in BCG-unresponsive NMIBC.